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ABSTRACT 
Background: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major 
cause of maternal and perinatal morbidity and mortality. The current approach to 
screening for PE is based on the identification of risk factors from maternal 
characteristics and medical history. This approach, however, fails to identify a high 
proportion of cases of PE and does not provide individualised, patient-specific 
results. An alternative approach is to combine maternal factors with biophysical and 
biochemical markers to estimate the individual probability of developing PE with 
higher detection rates. To date, no intervention is proven to reduce the risk of the 
disease, and several studies evaluating the use of aspirin for prevention of PE led to 
inconclusive results.  
Objectives: The aims of the studies included in this thesis are, first, to prospectively 
validate in a large European population a first-trimester algorithm for prediction of PE 
that combines maternal demographic characteristics and medical history with 
biophysical and biochemical markers; second, to compare this method of screening 
to the performance of currently used guidelines; third, to evaluate a possible 
beneficial effect of aspirin initiated at 11 to 14 weeks of gestation and at a dose of 
150 mg in the prevention of PE in a multicentre, double-blind, placebo-controlled 
randomised trial; and fourth, to analyse a potential role of cell-free DNA testing in the 
prediction of PE. 
Methods: Combined screening for PE was applied in the first or second trimester, 
and women found to be at high-risk in the first trimester were offered participation in 
a double-blind trial of aspirin against placebo in six European countries. We have 
recorded maternal characteristics and history, measured the uterine artery pulsatility 
index (UtPI) on ultrasound, the mean arterial pressure (MAP), serum concentration 
of pregnancy-associated plasma protein A (PAPP-A) and placental growth factor 
(PLGF). Pregnancy outcomes were obtained from the hospital maternity records. 
Bayes theorem was used to combine the a priori risk from maternal factors with the 
results of biomarker measurements and estimate individual probabilities. In the 
randomised trial, the analysis was performed in an intention-to-treat basis and the 
treatment effect on the primary outcome (the development of PE with delivery before 
37 weeks of gestation) was reported with 95% confidence interval (CI), and on 
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secondary outcomes with 99% CI. Cell-free DNA fetal fraction was compared with 
other first trimester markers for PE and in a case-control study.  
Results: Detection rates of combined screening, for a false-positive rate (FPR) of 
10%, were 89% (95% CI 79-96%), 75% (95% CI 70-80%) and 47% (95% CI 44-
51%) for PE <32 weeks, preterm PE and term disease, respectively. The 
performance of combined screening was superior to methods based on risk factors 
alone, both in the first and second trimesters. The use of aspirin by high-risk women 
reduced the incidence of preterm PE by 62% (adjusted odds ratio 0.38, 95% CI 0.20-
0.74). Secondary analyses have shown that the effect of aspirin was influenced by 
the level of compliance to treatment and was consistent in different subgroups 
according to maternal characteristics and obstetric history, but there was no 
evidence of beneficial effect of aspirin in women with chronic hypertension. Aspirin 
reduces the length of stay in NICU and costs through a reduction in premature births 
before 32 weeks due to PE. Fetal fraction on cell-free DNA testing correlates with 
other first trimester markers, but its role in screening for PE is uncertain. 
Conclusions: This thesis has demonstrated that combined screening for PE is 
superior to current guidelines based on maternal characteristics and history alone, 
and that aspirin, at a daily dose of 150 mg and given to high-risk patients from 11 to 
14 weeks until 36 weeks of gestation, reduces the incidence preterm PE and the 
length of stay in NICU. The effect of the medication depends on good adherence to 
treatment and is questionable in patients with chronic hypertension.  
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ABBREVIATIONS 
ACOG:  American College of Obstetricians and Gynecologists 
ART:   Assisted reproduction technologies 
ASPRE:  Combined multi-marker screening and randomised patient treatment 
with ASpirin for evidence-based PREeclampsia prevention trial 
AT1-AA:  Angiotensin II type 1-Receptor Autoantibody 
BCE:  Before the current era 
BMI:  Body mass index 
BP:   Blood pressure 
CCTU-UCL: Comprehensive Clinical Trials Unit, University College London 
CI:   Confidence interval 
CLASP: Collaborative Low-dose Aspirin Study in Pregnancy 
DNA:  Deoxyribonucleic acid 
DR:   Detection rate 
FGR:  Fetal growth restriction 
FMF:  Fetal Medicine Foundation 
FPR:   False-positive rate 
GBP or £: British pound 
GH:  Gestational hypertension 
HLA:   Human leukocyte antigen 
ISSHP:        International Society for the Study of Hypertension in Pregnancy 
IVF:  In vitro fertilisation 
kg:  Kilograms 
m:  Metres 
MAP:      Mean arterial pressure 
mg:   Milligrams 
MHC:   Major histocompatibility complex 
mmHg:  Millimetres of mercury 
mmol: Millimole  
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MoM:            Multiples of the median 
NICE:  National Institute for health and Clinical Excellence 
NK:  Natural killer cells 
NNT:   Number needed to treat 
OR:  Odds ratio 
PAPP-A: Pregnancy-associated plasma protein A 
PARIS:  Perinatal Antiplatelet Review of International Studies 
PE:   Preeclampsia 
PIH:  Pregnancy-induced hypertension (same as GH) 
PLGF:  Placental growth factor 
sFLT-1:  Soluble fms-like tyrosine kinase-1 
SPREE: Screening Program for Preeclampsia study 
TNF-: Tumour necrosis factor alpha 
UK:   United Kingdom 
US$:   American Dollars 
USA:   United States of America 
UtPI:       Uterine artery pulsatility index 
VEGF: Vascular endothelial growth factor 
µm:  Micrometres 
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1.1. Overview 
The first description of eclampsia, Greek word that means lightning, comes 
from ancient times, between the 5th and 4th centuries before the current era (BCE), 
when Hippocrates used the theory of imbalances in the four humours of the body 
(blood, phlegm, yellow bile, and black bile) to describe the cause of illness and 
disease (Bell, 2010). In 1739, François Boissier de Sauvages de Lacroix, a French 
physician and botanist, differentiated for the first time what is now known as epilepsy 
from the condition that causes convulsions in pregnancy, calling it eclampsia 
parturientum (Chesley, 1984). The finding that these seizures were accompanied by 
proteinuria came to light in 1840, shortly followed by recordings of high blood 
pressure (BP). The term preeclampsia (PE) was coined in 1894, describing the 
occurrence of hypertension and proteinuria in pregnancy, without eclamptic seizures 
(Chesley, 1984).  
PE is a serious complication that typically affects 2-3% of the pregnancies and 
remains one of the leading causes of maternal and perinatal morbidity and mortality 
(Duley, 2009). Over half a million women die each year due to preeclampsia-related 
causes, and more than 99% of these deaths occur in developing countries (Koonin 
et al., 1997; World Health Organization, 2005). The economic burden of the disease 
is a major public health issue in most countries. In the United States of America 
(USA), preeclampsia accounts for 18% of all maternal deaths and 15% of all 
premature births (Koonin et al., 1997; Kuklina et al., 2009). The cost of the disease in 
the first 12 months has been estimated at US$ 2.18 billion, and is disproportionally 
borne by premature births (Stevens et al., 2017).   
The disease is characterised by elevated BP and involvement of the kidneys 
with increased levels of protein in the urine (proteinuria) after 20 weeks of gestational 
age. Complications of PE include symptoms, signs and laboratory manifestations of 
maternal organ dysfunction, involving: the kidneys, with increased serum creatinine 
concentration; the liver, with elevated transaminases; the haematological system, 
with haemolysis and low platelet count; and neurological complications, including 
hyperreflexia, headache, visual disturbance, reduction of the visual sight, seizures 
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(eclampsia) and stroke, which constitutes the main cause of maternal mortality 
(Crovetto et al., 2013).  
A recent large meta-analysis has also confirmed that the occurrence of PE 
significantly increases the risk of adverse cardiovascular outcomes in the long-term. 
There is a four-fold increase in the risk of heart failure and a two-fold increase in 
coronary heart disease, cardiovascular disease-related death and stroke in women 
who experienced PE compared to those who did not (Wu et al., 2017). 
The aetiology of PE is still unclear. Previous studies have shown that 
abnormal development of the placenta is implicated, with an impaired trophoblastic 
invasion of the spiral arteries (Khong et al., 1986; Robertson et al., 1986; Lyall, 
2002). In healthy pregnancies, the muscular layer of these arteries, mainly in their 
myometrial portion, is remodelled to increase their diameter and capacitance, thus 
reducing the resistance to blood flow (Hamilton and Boyd, 1960; Brosens et al., 
1967). Due to unknown reasons, this process does not seem to happen in full in 
pregnancies affected by PE, leading to increased vascular resistance. This triggers 
the release of placental and endothelial substances with an imbalance in angiogenic 
factors (such as placental growth factor – PLGF – and vascular endothelial growth 
factor – VEGF) and anti-angiogenic factors (such as soluble fms-like tyrosine kinase-
1 – sFLT-1) that ultimately lead to increased BP, endothelial dysfunction and kidney 
injury (Robertson et al., 1967).  
Different entities have proposed various methods to identify women at high 
risk for the development of PE, mostly based on maternal characteristics (such as 
age and body mass index - BMI) and medical history. Frequently used guidelines are 
the ones suggested by the American College of Obstetricians and Gynecologists 
(ACOG) in the USA and by the National Institute for Health and Clinical Excellence 
(NICE) in the United Kingdom (UK) (Visintin et al., 2010; American College of 
Obstetricians and Gynecologists, 2013; American College of Obstetricians and 
Gynecologists, 2015). Nevertheless, these recommendations are primarily based on 
experts’ opinion and were rarely tested prospectively. Hence, their clinical 
performances are unknown.  
In the last few decades, authors have proposed an alternative Bayesian 
approach for individual-risk calculation based on logistic regression and competing 
 
11 
risk models that combine maternal characteristics and history with biophysical and 
biochemical markers shown to be different in women with PE in pre-clinical stages 
when compared to those that have an uncomplicated pregnancy, with higher 
reported predictive accuracy (Onwudiwe et al., 2008; Poon et al., 2009a; Odibo et 
al., 2015; Gabbay-Benziv et al., 2016; O'Gorman et al., 2016b). The most widely 
employed of these models are the ones published by the Fetal Medicine Foundation 
(FMF), from the UK (Poon et al., 2009a; O'Gorman et al., 2016b). These models, 
however, have been criticised due to the lack of studies of prospective external 
validation (Oliveira et al., 2014; Brunelli and Prefumo, 2015). 
As of prevention of PE in women at high risk, several pharmacological and 
non-pharmacological measures have been studied. The vast majority of the studies 
evaluated a possible beneficial effect of antiplatelet agents in the prevention of PE, 
commonly low-dose aspirin (Beaufils et al., 1985; CLASP Collaborative Group, 1994; 
Askie et al., 2007; Bujold et al., 2010; Roberge et al., 2012a; Roberge et al., 2012b; 
Bujold et al., 2014; Meher et al., 2017). However, their results are controversial, 
possibly due to heterogeneous methodologies applied regarding the method for 
identification of a high-risk population, different doses of aspirin prescribed and 
initiation of pharmacological prophylaxis at different gestational ages. Recent 
evidence suggests that aspirin is only beneficial in reducing the incidence of preterm 
and early-onset PE (but not term PE) and if started before 16 weeks of gestation at 
doses higher than 100 mg (Roberge et al., 2012a; Roberge et al., 2013a; Roberge et 
al., 2014; Roberge et al., 2017b).  
 
1.2. Definition of preeclampsia 
Preeclampsia is traditionally defined as the presence of hypertension and 
proteinuria in a previously normotensive woman, after 20 weeks of gestational age.  
Several diagnostic criteria have been proposed in the last few decades, but a 
widely accepted definition is the one published by the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) (Davey and MacGillivray, 1988; Brown 
et al., 2001). According to the ISSHP, preeclampsia is defined by increased blood 
pressure with systolic measurement ≥ 140 mmHg and/or diastolic measurement ≥ 90 
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mmHg on at least two occasions, four hours apart and after 20 weeks of gestational 
age, accompanied by proteinuria ≥ 300 mg in 24 hours or two positive dipstick 
analyses of at least ++ of protein on midstream or catheter urine samples, in the 
absence of a 24-hour collection. More recently, a spot urine protein/creatinine ratio ≥ 
30 mg per mmol was also added to the diagnostic criteria (Tranquilli et al., 2014).  
The occurrence of hypertension after 20 weeks of gestation without significant 
proteinuria or other signs of PE is classified as pregnancy-induced or gestational 
hypertension (PIH or GH). Other differential diagnoses include chronic or essential 
hypertension, usually manifested before 20 weeks of gestation, or white-coat 
hypertension (Tranquilli et al., 2014).   
Since hypertension is a necessary finding in PE, monitoring BP during 
antenatal care is fundamental. The use of validated automated devices following a 
standardised technique has been recommended (Poon et al., 2012).  
Recent definitions of PE have been used, and recent publications have 
disregarded the need for significant proteinuria, including amongst the diagnostic 
criteria any clinical or laboratory sign of end-organ damage, such as elevated liver 
enzymes, impaired renal function, neurological symptoms or fetal growth restriction 
(FGR) (Tranquilli et al., 2014). The proponents of this classification, however, 
acknowledge that the inclusion of proteinuria would ensure more specificity around 
the diagnosis when reporting clinical criteria for patients enrolled in scientific 
research (Tranquilli et al., 2014). For this research, the ISSHP classification and 
diagnostic criteria, including the need for proteinuria to be present, were chosen, as 
they represent a consensus of an appropriate and specific definition for use in 
research (Brown et al., 2001; Tranquilli et al., 2014).  
The contradictory findings of the literature regarding the accuracy of prediction 
and effectiveness of prevention of PE may be, to some extent, due to different 
definitions of PE used in various studies. An individual-patient data meta-analysis 
evaluating the use of anti-platelet agents for the prevention of PE, for example, found 
a very modest effect of aspirin in the prevention of PE but included 31 studies that 
comprised 14 different definitions of the disease (Askie et al., 2007).  
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1.3. Future cardiovascular risk 
 Although signs and symptoms of PE usually resolve after delivery, its 
occurrence impacts significantly on future maternal cardiovascular health. A recent 
systematic review and meta-analysis including over six million pregnancies and more 
than 258,000 cases of PE found a four-fold increase in the risk of heart failure and a 
two-fold increase in coronary heart disease, stroke and cardiovascular-related death 
among women who experienced PE compared to those who did not (Wu et al., 
2017). These risks seem to be closely related to the severity and earlier gestational 
age at the onset of the disease (Cirillo and Cohn, 2015; Christensen et al., 2017).  
It is unknown whether preeclampsia is the cause, predisposing women to 
cardiovascular complications in the future, or the consequence, being an early 
clinical manifestation of a suboptimal cardiovascular performance triggered by 
pregnancy. Nonetheless, pregnancy possibly constitutes a good window of 
opportunity to identify women at high-risk for cardiovascular disease. It would be 
reasonable to assume that preventing the onset of preeclampsia would impact in the 
cardiovascular profile later in life. Some authors even argue that the cardiovascular 
system may be the cause behind PE, mainly in late-onset forms of the disease, 
triggering placental hypoperfusion and the release of placental and endothelial 
mediators (Kalafat and Thilaganathan, 2017).   
 
1.4. Pathogenesis of preeclampsia – mechanism of disease 
 Although the exact mechanism of disease remains uncertain, the 
pathogenesis of PE is thought to occur in two different stages: a symptomless 
placental phase in which an abnormal trophoblastic invasion occurs between eight 
and 18 weeks of gestation, followed by an abnormal maternal vascular response that 
results in the release of inflammatory mediators (reason why the condition used to 
be called toxaemia), endothelial injury and dysfunction, eventually resulting in clinical 
manifestations including hypertension, proteinuria and oedema.  
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 1.4.1. Placental factors 
In humans, placentation involves remodelling of the maternal blood vessels to 
provide the fetus with sufficient nutrients from the mother’s blood supply. PE is 
thought to be caused by an impaired trophoblastic invasion of the spiral arteries, 
which are branches of the arcuate artery and ultimately of the uterine artery within 
the uterine wall (Figure 1).  
 
 
Figure 1 – Arterial blood supply to the uterus from the uterine and ovarian arteries, giving 
origin to the arcuate artery, the radial arteries and the spiral arteries in the myometrium and 
the endometrium; taken from Robertson (1976). 
 
The human placenta originates from cells denominated trophoblasts, which 
are subdivided into syncytiotrophoblasts and cytotrophoblasts. Approximately 11 to 
12 days after conception, the syncytiotrophoblasts infiltrate in the endothelium of the 
maternal capillaries to establish the uteroplacental circulation, under the influence of 
angiogenic growth factors, including VEGF and PLGF. About four to six weeks post-
conception, the cytotrophoblasts disrupt the maternal vascular integrity by invading 
the spiral arteries. This process leads to remodelling of the spiral arteries through the 
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destruction of the media layer muscular and elastic fibres, in a process known as 
trophoblastic invasion, which is thought to take place in two different stages of 
pregnancy: one initial wave of trophoblastic invasion, at approximately eight weeks 
of gestation and involving the decidual portion of the spiral arteries; and a second 
wave at the myometrial portion of the spiral arteries at 14 to 24 weeks of pregnancy 
(Redman, 1992; Lyall, 2002). The small-diameter (15-20 µm), high-resistance spiral 
arteries then become grossly dilated (300-500 µm), funnel-shaped and low-
resistance vessels (Figure 2), increasing the blood flow by about ten times to ensure 
sufficient blood supply to the developing fetus (Brosens et al., 1972). 
In healthy pregnancies, the uteroplacental circulation shows decreasing 
vascular resistance, markedly in the second trimester and mainly due to the 
remodelling process resulting in an increased capacitance of these vessels. Previous 
studies in which placental bed biopsies were performed have shown significantly 
reduced diameter of the spiral arteries in their myometrial portion in patients affected 
by PE when compared to healthy controls (Brosens et al., 1972; Pijnenborg et al., 
1991; Redman, 1992; Meekins et al., 1994; Lyall, 2002) (Figure 2).  
 
 
Figure 2  – Differences in diameter of the spiral arteries in non-pregnant women (left), in 
normal pregnancies after the remodelling of these vessels (right) and in pregnancies 
affected by PE (centre); adapted from Moffett-King (2002). 
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The impedance to blood flow in the uteroplacental circulation can be 
measured with ultrasound Doppler velocimetry techniques through the evaluation of 
the resistance on the uterine arteries and expressed as the uterine artery pulsatility 
index (UtPI), which shows a clear positive association with severity of the disease 
and histological changes (Olofsson et al., 1993).  
Not all pregnancies affected by PE, however, show signs of abnormal 
placentation. In PE that occurs at term, often histological studies of the placenta 
resemble those of normotensive pregnancies, and the diagnosis of PE is more likely 
to be confirmed before 32 weeks of gestation in those cases with abnormalities in 
the uteroplacental circulation (Ghidini et al., 1997). This highlights that high 
resistance in the uterine arteries not always predicts the development of PE but is 
rather a predisposing factor. 
Histopathology studies have also shown that acute atherosclerosis is a 
common feature in placentas from pregnancies affected by PE (Sheppard and 
Bonnar, 1981). However, this finding is not unique to PE, being also present in 
pregnancies complicated by fetal growth restriction, thrombophilia or miscarriage 
(Frusca et al., 1989). 
 
1.4.2. Immunologic and genetic factors 
 The cause of inadequate remodelling of the spiral during the placentation 
process in pregnancies affected by PE is unknown. Immunological and genetic 
theories have been implicated in the pathogenesis of the disease (Redman, 1992).  
The development of immunological tolerance to the semi-allogenic fetus, 
whose genes are half paternal, is facilitated by its reduced expression of the major 
histocompatibility complex (MHC) and the human leukocyte antigen (HLA) system, a 
mechanism that endeavours to avoid fetal cells from being innately rejected. 
Additionally, uterine natural killer (NK) cells initiate smooth muscle remodelling of the 
spiral arteries and regulate the trophoblastic invasion through the secretion of 
angiogenic growth factors and cytokines (Lash et al., 2011). These changes allow 
the innate immune system to adapt and thus prevent a pregnancy loss. A possible 
altered maternal immune response against the paternally-derived antigens on the 
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trophoblast is hypothesised as a potential aetiological factor (Sargent et al., 2006). 
Although identifying the exact immunological mechanism of origin is difficult while the 
immune system changes in early pregnancy are not entirely understood, this 
suggestion is corroborated by epidemiological studies that found a higher incidence 
of PE in pregnancies conceived with the use of donor egg (Martinez-Varea et al., 
2014). The immunological theories implicated in PE pathogenesis are also supported 
by previous studies that reported that higher intervals since the first coitus and co-
habitation to conception result in lower incidence of PE, which could be a 
consequence of development of tolerance to the HLA present in the semen (Marti 
and Herrmann, 1977; Dekker et al., 1998). Similarly, PE is more common in the first 
pregnancy, less common in subsequent pregnancies when the partner is the same; 
and changing partner or prolonged inter-pregnancy interval above ten years increase 
the risk of PE (Robillard et al., 1993; Dekker et al., 1998; Harutyunyan et al., 2013; 
Cormick et al., 2016).  
It seems that both maternal and fetal genotypes are implicated in the 
induction of immunological tolerance. Hence, a genetic predisposition may also be 
involved, and previous studies have shown that women with family history of PE are 
three times more likely to develop this condition (Arngrimsson et al., 1990; Duckitt 
and Harrington, 2005). Different genes were reported to be associated with 
increased risk of PE by regulating either blood pressure or trophoblastic invasion 
(Cooper and Liston, 1979; Chesley and Cooper, 1986). Hiby et al. (2008), for 
instance, found that a specific combination of maternal KIR (killer-cell 
immunoglobulin-like receptor) and fetal HLA-C genotypes is associated with an 
increased risk of PE. Other polymorphisms in various genes, such as tumour 
necrosis factor alpha (TNF-), angiotensinogen, 5,10-methylenetetrahydrofolate 
reductase and factor V Leiden, have also been associated with increased risk of PE 
(Morgan and Ward, 1999; Lachmeijer et al., 2001a; Lachmeijer et al., 2001b; 
Lachmeijer et al., 2001c; Benedetto et al., 2002; Heiskanen et al., 2002). 
A recent large meta-analyses found a higher risk of severe PE when the 
following gene mutations were found: coagulation factor V (proaccelerin) gene 
polymorphism rs6025, coagulation factor II (thrombin) gene mutation G20210A, 
leptin receptor (LEPR) gene polymorphism rs1137100 and the thrombophilic gene 
group (Fong et al., 2014). Another meta-analysis reported that the presence of a 
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prothrombin 20210A polymorphism increases by three times a patient’s risk of 
developing severe PE (Wang et al., 2014). However, the causality of these 
associations and the clinical utility of identifying such changes are yet to be 
examined in larger studies.  
 
1.4.3. Endothelial dysfunction 
 Endothelial dysfunction seems to be a significant contributor to the 
pathogenesis of PE. Endothelial cell activation or suppression are hypothesised to 
be secondary to placental hypoperfusion, ischaemia and infarction with release of 
inflammatory mediators, cytokines and reactive oxygen species, leading to 
significant intravascular inflammatory response (Gervasi et al., 2001; Tannetta et al., 
2003; Cindrova-Davies et al., 2007; Myatt and Webster, 2009).  
Infarcted placental cells also release receptor proteins such as sFLT-1, a 
protein produced by the syncytiotrophoblasts that is responsible for antagonising 
angiogenic growth factors, such as VEGF and PLGF (Kendall and Thomas, 1993; 
Huppertz, 2008). Previous studies have utilised the measurements of sFLT-1 and 
PLGF, or the ratio between the two, to increase the diagnostic accuracy in patients 
with suspected PE (Rana et al., 2012; Zeisler et al., 2016).  
The vascular injury leads to protein leakage and fluid retention in different 
organs and systems, causing, for example, proteinuria and generalised oedema. 
These abnormalities in the vascular system also cause an imbalance on levels of 
angiogenic proteins (i.e. VEGF and PLGF), and anti-angiogenic proteins (i.e. sFLT-1 
and soluble endoglin), further exacerbating the endothelial dysfunction (Maynard et 
al., 2003; Widmer et al., 2007; Murphy et al., 2013).  
Endothelial dysfunction also affects vascular tone and platelet activation. 
These changes are responsible for platelet dysfunction and thrombocytopaenia that 
can be present even before the onset of hypertension. Levels of prostacyclin, a 
vasodilator that inhibits platelet aggregation, are reduced in PE, while levels and 
thromboxane A2, a vasoconstrictor that promotes platelet aggregation, are increased 
(Bussolino and Benveniste, 1980; Bussolino and Camussi, 1980; Romero and Duffy, 
1980; Walsh, 1985; Romero et al., 1988).  
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In summary, it appears that poor placentation in the first half of the pregnancy 
is triggered by genetic factors that lead to poor immunological tolerance to the semi-
allogenic fetus. The suboptimal remodelling of the spiral arteries leads to the release 
inflammatory mediators, an imbalance in angiogenic and anti-angiogenic factors, and 
oxidative stress. This pre-symptomatic phase is responsible, in the second half of the 
pregnancy, for endothelial dysfunction that will exacerbate the production of 
inflammatory mediators and eventually lead to clinical manifestations of PE in 
different organs and systems (Figure 3).  
 
 
 Figure 3 – A summary of the pathogenesis of preeclampsia; taken from Powe et al. 
(2011). HTN: hypertension.  
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1.5. Screening for preeclampsia 
The current approach to screen for PE is by identifying risk factors from 
maternal characteristics and medical history and by measuring BP in antenatal 
clinics serially. The criteria to classify patients as high-risk and the management of 
such high-risk patients vary according to different protocols. In the UK, for example, 
the NICE guidelines are the recommended method of screening and patients with at 
least one high-risk factor or at least two moderate-risk factors should be reviewed by 
a healthcare professional every three weeks from 24 to 32 weeks of gestation and at 
least fortnightly from 32 weeks of gestation until delivery, as well as receive aspirin 
75 mg daily (Visintin et al., 2010). In the USA, in a statement published in 2017, the 
ACOG concludes that currently there are no accurate predictive tests for identifying 
women at high risk for PE and continues to recommend against other methods of 
screening, stating that a detailed medical history and serial BP measurements are 
the best tools to identify patients at high risk of PE.  
   
1.5.1. Maternal risk factors 
The vast majority of the studies conducted on prediction and prevention of PE 
and the protocols aiming to identify women at risk are based on maternal 
characteristics and medical history. Traditional risk factors are: 
 Maternal age: a wealth of studies published have suggested that the risk of PE 
increases with maternal age. In women older than 35 years of age, the risk of 
PE is doubled when compared to younger controls (Bianco et al., 1996; 
Lawoyin and Ani, 1996).  Mittendorf et al. (1996) reported that the risk of PE 
increases by 30-40% for every additional year after the age of 34 years. Further 
studies also support this finding, even after adjustment for confounders and 
interactions (Poon et al., 2010).   
 Parity, change of partner and inter-pregnancy interval: as previously 
mentioned, primigravidas seem to have a three-fold increase in the likelihood of 
developing PE (Duckitt and Harrington, 2005), even after adjustment for other 
risk factors such as maternal age, ethnic origin and body mass index (Luo et 
al., 2007), whereas women who have previously conceived appear to have 
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some degree of protection against PE even after a miscarriage (Dekker et al., 
1998; Dekker and Sibai, 1998). Multiparity reduces the risk of PE, but this 
protective effect is lost when the new pregnancy happens after a change of 
partner (Robillard et al., 1993). Similarly, epidemiological studies have shown 
an increase in the risk of PE with increasing inter-pregnancy interval, being 
equivalent of that of a primigravida when the interval is superior to ten years 
(Conde-Agudelo and Belizan, 2000a; Skjaerven et al., 2002). 
 Previous history of PE: experiencing PE in a previous pregnancy increases the 
risk of recurrence in subsequent pregnancies by seven to ten times (Campbell 
et al., 1985; Sibai et al., 1986; Lee et al., 2000; Mostello et al., 2002). A large 
meta-analysis including data from 94 studies reported a risk of recurrence of 
13.8%, being inversely related to the gestational age at delivery in the previous 
pregnancy affected by PE (van Oostwaard et al., 2015). 
 Ethnic origin: there is clear evidence showing an increased risk of PE in 
specific ethnic backgrounds. Afro-Caribbean ethnicity is associated with a 20-
50% increase in the risk of PE (Mittendorf et al., 1996; Sibai et al., 1997; Knuist 
et al., 1998; Mostello et al., 2002; Caughey et al., 2005). Women of South 
Asian origin are also at increased risk of PE. These findings may be mirroring a 
different cardiovascular profile, since these are groups also at increased risk of 
chronic hypertension and cardiovascular disease (Cappuccio, 1997; Cappuccio 
et al., 1997; Ramaraj and Chellappa, 2008; Khalil et al., 2013). East Asian 
origin, in contrast, is associated with lower risk of PE, possibly due to 
differences in BMI and nutritional factors (Xiao et al., 2014).   
 Obesity: obesity has become a significant public health issue in the last few 
decades (The G. B. D. Obesity Collaborators et al., 2017) and is an important 
risk factor for PE. Increased BMI confers a two to four-fold increase in the risk 
of PE (Mittendorf et al., 1996; Mostello et al., 2002; Duckitt and Harrington, 
2005), and this increase in risk is mainly due to a higher prevalence of late-
onset PE among overweight and obese women (Syngelaki et al., 2011; Durst et 
al., 2016). 
 Assisted reproduction technologies (ART): various studies show an increased 
risk of PE following conception with ART (Maman et al., 1998; Jackson et al., 
2004; Shevell et al., 2005; Trogstad et al., 2009). It is unclear whether it is the 
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in vitro fertilisation (IVF) or the ovulation induction process that increases the 
risk of PE. A study including more than 47 thousand pregnancies has shown 
that conception by IVF increases the risk of PE and the risk is even higher in 
frozen-thawed cycles compared to fresh cycles (Opdahl et al., 2015). Women 
who conceived by IVF with donor egg are also at significantly higher risk 
compared to those who undergo IVF with autologous egg (Masoudian et al., 
2016; Simeone et al., 2016).  
 Family history of PE: the risk of PE is increased three to four-fold in women 
with a family history of the disease occurring in the mother or the sister 
(Arngrimsson et al., 1990; Cincotta and Brennecke, 1998).   
 Diabetes mellitus: the risk of developing PE in women with type I diabetes 
appears to be more than three times higher than in the general population 
(Garner et al., 1990; Ros et al., 1998; Lee et al., 2000). 
 Chronic hypertension: pre-existing hypertension (or chronic hypertension 
diagnosed before 20 weeks of gestation) doubles the risk of PE (Conde-
Agudelo and Belizan, 2000b) and women with this condition are more likely to 
develop early-onset and severe forms of the disease (Catov et al., 2007).  
 Renal disease: women with renal disease are more likely to develop PE with a 
three-fold increase in risk (Martinell et al., 1990; Maruotti et al., 2012).  
 Autoimmune disease: the presence of anti-cardiolipin antibodies or lupus 
anticoagulant has been shown to significantly increase the risk of PE (Branch 
et al., 1989; Sletnes et al., 1992; Pattison et al., 1993; Dreyfus et al., 2001). A 
case-control study has also found women who experienced PE to be six times 
more likely to have an autoimmune disease such as systemic lupus 
erythematosus (Stamilio et al., 2000). 
 
1.5.2. Current guidelines 
In the UK, the NICE guidelines were published in 2008 and revised in 2010 
(Visintin et al., 2010). These guidelines state that women should be considered at 
high risk for PE if they have any high-risk factor or two or more moderate-risk factors.  
The high-risk factors are history of hypertensive disease in a previous 
pregnancy, chronic kidney disease, autoimmune disease, diabetes mellitus and 
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chronic hypertension; the moderate-risk factors are first pregnancy, maternal age of 
40 years or more, inter-pregnancy interval of more than ten years, BMI at first visit of 
35 kg/m2 or more, and family history of PE. According to NICE, all high-risk women 
should be offered low-dose aspirin (75 mg daily) (Visintin et al., 2010). 
In the USA, according to the ACOG, taking a medical history to evaluate for 
risk factors is currently the best and only recommended screening approach for PE; 
the risk factors are nulliparity, age above 40 years, BMI higher than 30 kg/m2, 
conception by IVF, history of previous pregnancy with PE, family history of PE, 
chronic hypertension, chronic renal disease, diabetes mellitus, systemic lupus 
erythematosus or thrombophilia (American College of Obstetricians and 
Gynecologists, 2015). According to ACOG use of aspirin should be reserved for 
women with a history of PE in two or more previous pregnancies or at least one 
previous pregnancy affected by PE requiring delivery before 34 weeks of gestation 
(American College of Obstetricians and Gynecologists, 2013).  
These national guidelines were rarely tested in prospective cohorts and do not 
seem to perform well in studies that evaluated their accuracies (Verghese et al., 
2012). The approaches recommended by NICE and ACOG essentially attribute 
similar weights to each risk factor and does not take in account protective factors, 
such as multiparity without previous history of PE. In the recently published 
“Screening Program for Preeclampsia” (SPREE) study, only 40.8% of the cases of 
preterm PE were identified in the first trimester by the NICE guidelines and less than 
a quarter (23%) of the patients at high risk were prescribed aspirin, suggesting low 
compliance to the protocol currently used in the UK (Tan et al., 2018).  
 
1.5.3. Biomarkers 
 Several markers of preeclampsia were described in the last few decades and 
could potentially be used in screening for PE. However, no marker has shown to be 
accurate enough when used isolated. Instead, a combination of markers in a 
predictive model that also takes into account the interactions between them can 
increase accuracy and reduce false-positive results. The most commonly used and 
with higher performance are biophysical markers such as BP and uterine artery 
Doppler, and biochemical markers such as pregnancy-associated plasma protein 
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(PAPP-A), placental growth factor (PLGF) and soluble fms-like tyrosine kinase-1 
(sFLT-1).  
 
1.5.3.1. Biophysical markers 
Blood pressure 
 Previous studies have consistently shown that women destined to develop PE 
have elevated BP already in the first and second trimesters before other clinical 
manifestations of the disease appear (Moutquin et al., 1985; Higgins et al., 1997; 
Poon et al., 2008). The difference between BP levels in women who will later present 
with PE and unaffected pregnancies is more prominent in cases of severe and early-
onset disease than in cases of PE at term (O'Gorman et al., 2016b). 
 Mercury sphygmomanometers have traditionally been used to measure BP in 
antenatal care, but concerns regarding their accuracy and safety have been raised 
(Markandu et al., 2000). The use of automated devices may be more accurate, and a 
standardised technique has been described for reliable measurement of MAP in 
pregnancy (Poon et al., 2012), which involves two readings in each arm at the level 
of the heart, with adequate cuff size and after five minutes of rest. These readings 
are then used to calculate the MAP and its value, just like all other biomarkers, is 
then expressed in multiples of the median (MoM) after adjustment for gestational age 
and maternal factors that influence the MAP.   
 
Uterine artery Doppler 
 Assessment of the resistance to blood flow in the uterine arteries was first 
described in 1983 (Campbell et al., 1983). The literature consistently shows that 
higher resistance levels, reported as high pulsatility index (PI) or resistance index 
(RI), correlate with both histological studies and clinical severity of PE. As with MAP, 
the earlier and more severe PE develops, the more pronounced the differences in 
mean UtPI from cases to controls, being poorly predictive of term disease 
(O'Gorman et al., 2016b). The use of indices is preferred over the reporting of 
subjective markers of high resistance like early diastolic notch (Figure 4), which are 
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poorly predictive of adverse pregnancy outcomes (Kaminopetros et al., 1991; 
Olofsson et al., 1993).  
 
 
Figure 4 – (a) Normal uterine artery blood flow Doppler waveform, with an abundance of 
end-diastolic flow (arrow); (b) waveform characteristic of high-resistance blood flow, with a 
steeper systolic upslope when compared to the normal waveform, with an early diastolic 
notch (yellow arrow) and reduced end-diastolic flow velocity (courtesy of Prof Kypros 
Nicolaides, Fetal Medicine Foundation, UK). 
 
The PI is defined by the difference between the peak systolic velocity and the 
minimum diastolic velocity, divided by the peak systolic velocity. The RI is 
determined by the same difference divided by the mean velocity.   
On transabdominal or transvaginal ultrasound, the uterine artery is identified 
with the use of colour Doppler and pulsed wave is applied to measure blood flow 
velocity. In the first trimester or at a transvaginal ultrasound at any stage, the uterine 
artery is identified at the level of the internal cervical os. After measuring the right 
and left uterine arteries PI, the mean UtPI is expressed in MoM values after 
adjustment for maternal characteristics and gestational age. 
 During transabdominal ultrasound in the second trimester, due to difficult 
visualisation of the cervix, this vessel is identified in its apparent cross-over with the 
external iliac artery. When technically possible, transvaginal measurements should 
be avoided, as they result in higher PI values (Plasencia et al., 2008; Plasencia et 
al., 2011).   
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1.5.3.2. Biochemical markers 
 A large number of biochemical markers have been evaluated for clinical use 
in the prediction of PE. At present, no marker used in isolation can accurately predict 
the occurrence of PE. In general, the altered levels of biochemical markers in 
patients who will later experience PE are a preclinical sign of impaired placentation, 
release of inflammatory factors, platelet activation, endothelial dysfunction, abnormal 
oxidative stress or maternal renal impairment. Two of the most extensively 
investigated biomarkers are PAPP-A and PLGF, placental products that are 
significantly lower, even in the first trimester, in patients who will later experience 
early and severe forms of PE (O'Gorman et al., 2016b). They can be measured in 
automated machines with reproducible results provided within 30 to 40 minutes after 
blood sampling. These markers are also influenced by gestational age and different 
maternal characteristics. Thus, their results should also be expressed in MoM 
values, after adjustment for these confounders (Spencer et al., 2006; Poon et al., 
2009b; Lai et al., 2013; Lai et al., 2014; Tsiakkas et al., 2015; Wright et al., 2015a; 
Khalil et al., 2016; Tsiakkas et al., 2016a; Andrietti et al., 2017). Some other 
markers, such as sFLT-1, are only predictive when used in the second or third 
trimester, being no different in the first trimester in patients who will later develop PE 
from normotensive controls (Akolekar et al., 2010).  
  
Pregnancy-associated plasma protein A (PAPP-A) 
PAPP-A is secreted by the syncytiotrophoblasts and plays an essential role in 
placental growth and development. Its measurement is widely used in first-trimester 
screening for fetal chromosomal abnormalities, given the fact that pregnancies 
affected by trisomy 21 (Down’s syndrome), trisomy 18 (Edward’s syndrome) and 
trisomy 13 (Patau’s syndrome), are associated with significantly reduced PAPP-A 
levels (Bersinger et al., 1994; Spencer et al., 1999; Kagan et al., 2008). Pregnancies 
affected by PE have also been shown to have significantly lower PAPP-A at all 
stages of pregnancy before the onset of the disease (Poon et al., 2009b). However, 
the isolated use of PAPP-A below the 5th percentile (0.4 MoM) predicts only 8-23% 
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of the cases of PE, with reported odds ratio (OR) between 1.5 and 4.6 (Smith et al., 
2002; Yaron et al., 2002; Dugoff et al., 2004; Spencer et al., 2005). 
  
Placental growth factor (PLGF) 
PLGF is an angiogenic factor, part of the vascular endothelial growth factor 
family, secreted by the cytotrophoblasts. Its levels are significantly decreased in the 
first trimester in women who will experience PE (Ahmad and Ahmed, 2004; Levine et 
al., 2004; Stepan et al., 2007a; Stepan et al., 2007b; Akolekar et al., 2008; 
O'Gorman et al., 2016b).  
 
1.5.5. Inversion of the pyramid of prenatal care 
The current approach to antenatal care is based on a booking visit in which 
the health professional obtains a detailed maternal medical history to identify risk 
factors for pregnancy complications. The intervals between visits are large up until 
the third trimester, being then shortened to fortnightly or weekly visits, aiming to 
identify as early as possible complications that typically appear in the second half of 
the pregnancy, such as PE, gestational diabetes mellitus and obstetric cholestasis. 
Hence, the BP should be measured in all antenatal visits. In 1929, the Ministry of 
Health in the UK issued a Memorandum on Antenatal Clinics recommending that 
women should first be seen at 16 weeks, then at 24 and 28 weeks, fortnightly 
thereafter until 36 weeks and then weekly until delivery (Ministry of Health Report, 
1929). However, there is a clear trend in the literature in recent years toward the 
attempt to predict pregnancy complications in the first trimester, allowing for early 
initiation of preventive measures and close surveillance of high-risk pregnancies. 
This concept has been referred to as “inversion of the pyramid of antenatal care” 
(Nicolaides, 2011) (Figure 5). 
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Figure 5 – Left: the traditional model of prenatal care established in 1929; Right: the inverted 
pyramid of antenatal care with screening for pregnancy complications at 12 weeks and 
stratification of care after the first visit; taken from Nicolaides (2011). 
  
1.5.6. Combined screening 
 An alternative method of screening for PE is based on the combination of 
biophysical and biochemical markers with maternal characteristics and medical 
history to obtain an individual probability of developing PE, in a similar approach to 
that of the combined screening test for Down’s syndrome. In these predictive 
models, the a priori risk based on maternal characteristics and history is then 
adjusted (Bayes’ theorem) after addition of biomarkers measurement through a 
mathematical equation derived from logistic regression or competing risk models 
(O'Gorman et al., 2016b).  
 Logistic regression models produce risk estimates based on the multiplication 
of regression coefficients by the individual value of each variable used in the model 
when predicting a categorical outcome variable. This combined method of screening 
is performed using equations obtained by logistic regression analysis to derive the a 
priori risks of PE from maternal characteristics. The maternal factors-related a priori 
risks are then multiplied by the likelihood ratios of the biophysical and biochemical 
markers to derive the a posteriori risks (Akolekar et al., 2011). It is hypothesised that 
for each predictor in the model development, ten events should have occurred to 
avoid overfitting (Vittinghoff and McCulloch, 2007).     
 In a competing risk model (Kalbfleisch and Prentice, 2002), it is assumed that 
if the pregnancy were to continue indefinitely, all women would develop this 
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condition. Therefore, there is a competition between the delivery with PE and 
delivery for other reasons. The distribution of gestational age at birth with PE is then 
obtained by applying Bayes’ theorem (Wright et al., 2012; Akolekar et al., 2013; 
Wright et al., 2015b; Gallo et al., 2016; O'Gorman et al., 2016b) to combine the prior 
distribution based on maternal characteristics with likelihoods of the time to delivery 
with PE given by biomarkers measurements (adjusted for confounding 
characteristics and expressed in MoM values). A recent study by O'Gorman et al. 
(2016b), including 35,948 pregnancies between 11 and 13 weeks of gestation, 
reported that while maternal characteristics and history alone would detect only 49% 
of the cases of preterm PE, screening by combining maternal characteristics and 
history with MAP, mean UtPI and PLGF predicted 89% of the cases of PE requiring 
delivery before 32 weeks, 75% of the cases of preterm PE and 47% of the cases of 
term PE, for a fixed false-positive rate (FPR) of 10%. In this study, the addition of 
PAPP-A to the predictive model did not significantly increase the detection rates 
when PLGF was included, suggesting some degree of overlap and interaction 
between the two biochemical markers (O'Gorman et al., 2016b).   
Different combinations of markers yield various detection rates for the same 
FPR and would be useful, for example, in low-income settings where biochemical 
markers measurement might not be available. Another study, performed in a low-
resource area of Brazil using only maternal factors and MAP in the first trimester 
predicted 67% of the cases of preterm PE at a 10% FPR (Rocha et al., 2017).  
Predictive models have been criticised because of the possibility of a better 
performance of the algorithm in the cohort used to develop the model than in 
prospective validation studies, a phenomenon known as overfitting. Other authors 
criticise the use of these predictive models because they often lack cross-validation 
and external validation studies (Oliveira et al., 2014; Brunelli and Prefumo, 2015; 
Kleinrouweler et al., 2016).   
 
1.6. Prevention of preeclampsia with aspirin 
 Aspirin is one of the oldest medications still in widespread use. The utilisation 
of aspirin-related compounds derived from the willow tree bark, “salix”, and reports 
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can be found in Egyptian papyrus scrolls dating back to 1534 BCE (Ebers, 2018). 
Hippocrates and his disciples also extracted powder from the same tree to treat 
headaches and fevers (Miner and Hoffhines, 2007). In 1828, Johann Buchner 
extracted the active ingredient of the willow plant and called it “salicin”, word that 
represents willow in Latin; a few years later the sodium salicylate was treated with 
acetyl chloride to produce acetylsalicylic acid, and the first tablets were industrially 
produced in 1915 (Miner and Hoffhines, 2007). In 1971, Vale, Samuelson and 
Bergstrom were awarded a Nobel prize after elucidating the mechanism of action of 
the drug; nowadays, aspirin is one of the most commonly prescribed medications, 
taken by more than 50 million people for prevention of cardiovascular disease and 
with about 40,000 tons consumed every year (Navaratnam et al., 2016).    
 Several interventions, including non-pharmacological (such as bed rest and 
reduction of salt intake) and pharmacological measures, have been studied for the 
prevention of PE, and aspirin has been the most widely considered pharmacological 
intervention with this purpose.  
 
1.6.1. First reports 
 In 1978,  Goodlin et al. (1978) reported in a prestigious medical journal a case 
of a woman who was pregnant for the third time, having had two previous 
pregnancies affected by severe hypertension, thrombocytopaenia and fetal growth 
restriction, requiring premature deliveries at around 30 weeks of gestation. In the 
third pregnancy, platelets were markedly reduced already at 15 weeks of gestation, 
but after initiation of treatment with aspirin (600 mg three times a day), the platelet 
count slowly increased to twice as high values, and no signs of hypertension were 
present at 32 weeks of gestation. At that stage, aspirin was ceased due to the fear of 
side effects to the fetus such as premature closure of the arterial duct, and there was 
an acute development of hypertension and thrombocytopaenia again, suggesting a 
potential beneficial effect of aspirin in high-risk cases.  
 One year later,  Crandon and Isherwood (1979) published, in the same 
periodic, the results of a questionnaire survey administered to 964 primigravidae 
women, and those who had frequently taken aspirin or non-steroidal anti-
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inflammatory drugs during pregnancy had a significantly lower incidence of PE 
compared to those who did not take these drugs regularly.  
  
1.6.2. Mechanism of action of aspirin  
 The mechanism by which aspirin could potentially prevent PE is unclear. 
Theories include the inhibition of platelet activation that occurs in PE through 
changes in the prostacyclin and thromboxane A2 cascade, improvement in 
placentation, and anti-inflammatory effects on endothelial cells (Redman et al., 1978; 
Crandon and Isherwood, 1979).  
 An in vitro study with a model of placental cells and the addition of serum from 
women with and without PE has shown that in PE the production of PLGF and its 
gene expression are reduced compared to controls, cytokines levels are altered, the 
differentiation of placental cells is abnormal, and markers of cellular apoptosis are 
increased. All these alterations were reverted to normal levels with the addition 
aspirin to the experiment (Panagodage et al., 2016).  
 
1.6.3. Randomised trials 
 In the first randomised trial on the effect of aspirin on pregnancy 
complications,  Beaufils et al. (1985) randomised 102 women at high risk of PE or 
fetal growth restriction (FGR) to receive 150 mg of aspirin daily or no treatment from 
12 weeks of gestation. PE occurred in six patients and severe FGR or fetal death in 
nine patients in the non-treatment group, but none of the patients in the aspirin group 
was affected by these complications.  
 Similarly, a small placebo-controlled trial randomised 46 primigravidae women 
judged to be at high risk of hypertensive disorders at 28 weeks of gestation to 
receive aspirin at a daily dose of 60 mg or placebo. The incidence of PE and PIH 
was markedly reduced in the aspirin group (Wallenburg et al., 1986) without a 
significant increase in side-effects.  
Many other intervention studies followed, and part of the excitement about the 
potential beneficial effect of aspirin vanished when a large landmark study known as 
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CLASP trial (Collaborative Low-dose Aspirin Study in Pregnancy) showed that, 
despite being safe for the mother and the child, aspirin at a daily dose of 60 mg did 
not reduce the incidence of PE when compared to placebo (CLASP Collaborative 
Group, 1994). The study included 9,364 women at risk of PE or FGR due to medical 
history and also pregnancies already diagnosed with PE and FGR. There was, 
however, a significant trend towards progressively greater reductions in PE the more 
preterm the delivery occurred. It is now believed that the negative results of this trial 
could have been due to the low dose used (60 mg), inadequate selection of high-risk 
patients and late initiation of aspirin (treatment was started at different stages 
between 12 and 32 weeks).   
 
1.6.4. Meta-analyses 
 In 2001, a meta-analysis including more than 30,000 pregnancies from 39 
trials reported a 15% reduction in the risk of PE among women who used anti-
platelet agents during pregnancy (relative risk 0.85, 95% CI 0.78-0.92) (Duley et al., 
2001). 
 Similarly, the PARIS (Perinatal Antiplatelet Review of International Studies) 
study was a meta-analysis of individual patient data including 31 randomised trials 
evaluating the effect of anti-platelet agents on the prevention of PE, 23 of which used 
aspirin (Askie et al., 2007). This study found a significant but very modest 10% 
reduction of PE in the treatment group compared to placebo or no treatment (relative 
risk 0.90, 95% CI 0.84-0.97), but no differences in stillbirth or delivery of small for 
gestational age infants. Aspirin again appeared to be safe, as adverse events were 
similar between the groups. In the trials included in the PARIS study, 14 different 
definitions of PE were used. A large proportion of the studies used aspirin at a daily 
dose that was lower than 100 mg (21/23), and 20 of 23 studies started the treatment 
after 15 weeks of gestation.  
Evaluating the platelet function in pregnant women making use of aspirin,  
Caron et al. (2009) demonstrated that, at 81 mg, the standard dose in North 
America, about 30% of the women were non-responders, with no alterations in 
platelet function. When the dose was doubled (162 mg), non-responsiveness was 
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less than 5%. This finding was supported by a later meta-analysis including 20,909 
pregnant women, which reported a dose-dependent and a significant reduction and 
in PE cases when aspirin is initiated before 16 weeks of gestation, but not when 
treatment is started after this gestational age or with lower doses (Roberge et al., 
2017b). Previous meta-analyses published by the same group have also shown a 
significant risk reduction for PE, FGR and perinatal death with aspirin started before 
16 weeks of gestation (Roberge et al., 2012a; Roberge et al., 2013b). Equally, there 
was a very pronounced reduction in the occurrence of preterm PE, but no statistically 
significant reduction of PE at term (Roberge et al., 2012a). The studies by Roberge 
et al. were not meta-analyses of individual patient data and, for this reason, could 
have overestimated the beneficial effect of aspirin. However, their results show a 
benefit only when aspirin is started before 16 weeks of gestation, at a dose higher 
than 100 mg and when the outcome measure is preterm PE rather than term PE or 
all PE cases.  
In a recent secondary analysis of the PARIS study (Meher et al., 2017), the 
authors did not find differences when the results were stratified by gestational age at 
which treatment was initiated (before or after 16 weeks of gestation) and by dose of 
aspirin given (higher or lower than 75 mg), but the authors did not analyse a 
combination of both (dose > 75 mg initiated before 16 weeks of gestation) (Roberge 
et al., 2017a).   
In view of the conflicting results reported in the literature, the aims of the 
publications included in this thesis are, first, to prospectively test and validate the 
FMF algorithm for prediction of PE in a large European population; second, to 
compare this method of screening to the performance of currently used guidelines; 
third, to evaluate a possible beneficial effect of aspirin initiated at 11 to 14 weeks of 
gestation and at a dose of 150 mg in the prevention of PE in a multicentre double-
blind placebo-controlled randomised trial; and fourth, to analyse a potential role of 
cell-free DNA testing in the prediction of PE. My contribution for each one of the 
studies included in this thesis is summarised in the Appendix. 
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2. Validation of combined screening for 
preeclampsia
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The second chapter of this thesis consists of three publications. The first two 
report the findings of a validation study performed before the initiation of the 
Combined multi-marker screening and randomised patient treatment with ASpirin for 
evidence-based PREeclampsia prevention (ASPRE) trial, denominated Screening 
Quality Study. The third one reports the validation of a similar approach to screening 
for PE in the Australian population, in the second trimester of pregnancy, using 
maternal factors, MAP and UtPI. 
In the first publication (O'Gorman et al., 2017b), we report the accuracy of the 
screening test in a prospective application of the FMF algorithm for prediction of 
preterm PE in the first trimester in hospitals participating of the subsequent ASPRE 
trial. This study was proposed to test the screening prospectively in a large 
European population. Patients attending first-trimester combined screening for 
chromosomal abnormalities at 11 to 13 weeks of gestation were also offered 
combined screening for PE at the same time using collection of maternal 
characteristics and medical history, measurement of MAP and UtPI according to 
previously published techniques (Plasencia et al., 2007; Poon et al., 2012) and 
maternal serum biochemistry. Inclusion criteria were defined as maternal age > 18 
years; singleton pregnancy; live fetus at 11 to 13 weeks of gestation; no serious 
mental illness or learning difficulty; and informed and written consent. The individual 
risk for preterm PE was calculated and was not disclosed to the patients. 8,775 
patients were screened, and the incidence of PE was 2.7% (239), with PE requiring 
delivery before 32 weeks of gestation affecting 0.2% (17) and preterm PE 0.7% (59) 
of the pregnancies. The detection rates were 89% (95% CI 79-96%), 75% (95% CI 
70-80%) and 47% (95% CI 44-51%) for PE < 32 weeks, preterm PE and term 
disease, respectively. These figures were similar to those reported in the 
development of the algorithm (O'Gorman et al., 2016b).   
In the second publication (O'Gorman et al., 2017a), we compared the 
performance of the screening test to current policies of screening based on maternal 
factors alone (NICE guidelines and ACOG recommendations) in the same cohort of 
8,775 patients. Whereas combined screening detected 75% (95% CI 70-80%) of the 
cases of preterm PE at a 10% FPR, screening with use of NICE guidelines identified 
39% (95% CI 27-53%) of PE < 37 weeks at 10.2% FPR and screening with use of 
ACOG risk factors detected 90% (95% CI 79-96%) of PE <37 weeks, at a much 
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higher FPR of 64.2%. Screening based on the ACOG recommendations for the use 
of aspirin detected only 5% (95% CI 2-14%) of the preterm PE cases. This illustrates 
that methods based on maternal history and characteristics alone have either low 
detection rates or high FPR.  
Other studies also validated the first trimester combined screening by 
applying the FMF algorithm in different populations, with similar results (Park et al., 
2013; Park et al., 2015; Lobo et al., 2017).  
A similar way of screening through the combination of multiple markers with 
maternal factors can also be used in the second trimester (Gallo et al., 2016) or the 
third trimester (Tayyar et al., 2014; Tsiakkas et al., 2016b). This is particularly 
important to reassess risks in models in which care is stratified according to previous 
screening tests results (Litwinska et al., 2017) or in settings where a significant 
proportion of patients attend antenatal care too late for first-trimester screening, after 
14 weeks of gestation (Gross et al., 2012; Muhwava et al., 2016). Although no 
intervention appears to reduce the incidence of PE when started after 20 weeks of 
gestation, cases identified late as high risk may benefit from increased surveillance. 
Hence, in the third publication presented in this chapter (Al-Amin et al., 2018), we 
prospectively tested the combined screening for PE in the Australian population in 
the second trimester, in a cohort of 543 women attending fetal morphology 
ultrasound at 19 to 22 weeks of gestation. Combined screening detected all cases of 
preterm PE, performing better and with a lower screen-positive rate than NICE 
guidelines and ACOG recommendations criteria.   
 
Strengths and limitations 
The main limitation of the three studies presented in this chapter is the 
relatively small incidence of early-onset and preterm PE, leading to inevitably wide 
confidence intervals. Specifically, the number of women screened in the third study 
is limited. Nevertheless, the detection rates with the predictive model in all three 
studies are similar to those reported in previously published studies (Wright et al., 
2012; Akolekar et al., 2013; Gallo et al., 2016; O'Gorman et al., 2016b). 
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Publications 
1. https://www.ncbi.nlm.nih.gov/pubmed/28067011 
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar 
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3. Development and design of the ASPRE trial
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This chapter is based on the publication of the Combined multi-marker 
screening and randomised patient treatment with ASpirin for evidence-based 
PREeclampsia prevention (ASPRE) study protocol in an open access journal 
(O'Gorman et al., 2016a). The ASPRE trial was designed to address the controversy 
as to whether aspirin reduces or not the risk of PE, brought to light by previous 
studies that were very heterogeneous regarding the selection of high-risk patients, 
dose and time of initiation of treatment with aspirin. Given that results of recent meta-
analyses showed an apparent effect of aspirin at doses of 100 mg or higher and start 
of treatment before 16 weeks of gestation on the incidence of preterm (but not term) 
PE (Bujold et al., 2010; Roberge et al., 2012b), we designed a large multicentre, 
double-blind, placebo-controlled trial starting aspirin at 11 to 14 weeks of gestation at 
a dose of 150 mg daily, at night, to women deemed to be at high risk by the FMF 
combined predictive model at the same time of the 11 to 13 weeks ultrasound for 
chromosomal abnormalities screening, until 36 weeks of gestation or birth if it 
happened before 36 weeks. 
All patients attending first-trimester combined screening for chromosomal 
abnormalities at 11 to 13 weeks of gestation would also be offered combined 
screening for PE at the same time using collection of maternal characteristics and 
medical history, measurement of MAP and UtPI on ultrasound by previously 
published techniques (Plasencia et al., 2007; Poon et al., 2012) and measurement of 
serum PAPP-A and PLGF. The individual risk of preterm PE would be calculated 
through equations embedded in the ultrasound reporting software once the results 
were received and the patient would be informed about the risk. Patients considered 
to be at high risk, with the probability of developing preterm PE above a certain 
threshold chosen to result in a 10% screen-positive rate, would then be invited to 
participate in the randomised trial of aspirin versus placebo.   
There were 13 academic hospitals participating in the trial, including six 
centres in the UK; three in Spain, and one in each of Italy, Belgium, Greece and 
Israel. Adherence to the study protocol would be monitored by the Comprehensive 
Clinical Trials Unit, University College London (CCTU-UCL).   
Inclusion criteria for screening were defined as maternal age > 18 years; 
singleton pregnancy; live fetus at 11 to 13 weeks of gestation; English, Italian, 
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Spanish, French, Dutch or Greek-speaking (otherwise interpreters would be used); 
and informed and written consent. Patients younger than 18 years, multiple 
pregnancies, cases of major fetal abnormality identified at the 11 to 13 weeks 
assessment and women who were unconscious, severely ill, those with learning 
difficulties or serious mental illness would be excluded from screening.  
High-risk patients would be excluded from randomisation if they were taking 
low-dose aspirin regularly, previously diagnosed with bleeding disorders (such as 
Von Willebrand’ s disease), peptic ulceration, hypersensitivity to aspirin or they were 
already on long-term non-steroidal anti-inflammatory medication. Cases of 
concurrent participation in another drug trial at any time within the previous 28 days, 
or with any other reason the clinical investigators thought would prevent the potential 
participant from complying with the trial protocol would also be excluded from the 
randomised study.  
The sample size was calculated assuming that the screen-positive rate would 
be 10%, that 76% of the cases of preterm PE would be identified and that 60% of the 
high-risk women would agree to participate in the study. We would need to screen 
29,330 pregnancies to identify 2,933 high-risk cases and randomise 1,760 to detect 
a possible significant effect of aspirin in reducing the incidence of preterm PE by 
50% when compared to placebo at a 5% significance level and with 90% statistical 
power. This number was also calculated to account for attrition, expecting a 10% 
loss to follow-up or drop-out rate. 
 
Strengths and limitations 
The ASPRE trial was designed to be the largest multicentre, double-blind, 
placebo-controlled trial to date to examine the effect of aspirin in women at high-risk 
for preterm PE identified in the first trimester. To maximise the potential benefit of 
aspirin in the prevention of preterm PE and given the findings of recent literature, a 
higher dose of aspirin (150 mg) would be used to avoid resistance. The main 
limitation of the study would be the lack of long-term follow-up of the offspring, as the 
outcome collection was limited to the early neonatal period. 
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4. Multicentre double-blind placebo-controlled 
trial with aspirin – the ASPRE trial
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This chapter consists of the main publication of this work. It reflects the results 
of the Combined multi-marker screening and randomised patient treatment with 
ASpirin for evidence-based PREeclampsia prevention trial (ASPRE), a large 
multicentre double-blind, placebo-controlled intervention study (Rolnik et al., 2017b).  
My contribution to the ASPRE study included overall coordination of the trial, 
training of staff in all sites prior to commencement, recruitment and follow-up of 
patients at King’s College Hospital (London, UK), reporting of adverse events to 
CCTU-UCL, oversight of data collection in all sites, collection of pregnancy 
outcomes, quality assurance of biomarker measurements in all sites, and writing of 
the manuscript. 
In total, 26,941 women underwent first-trimester screening for PE by a 
combination of maternal characteristics and history, MAP, UtPI, PAPP-A and PLGF. 
Of those, 2,971 (11%) were found to be at high risk for developing PE, using a risk 
cut-off of 1 in 100. After counselling, 1,776 (60%) high-risk patients were eligible and 
agreed to randomisation, 878 allocated to blindly receive aspirin at a dose of 150 mg 
and 898 to receive placebo daily from 11 to 14 until 36 weeks of gestation. The final 
number of patients in each group were 798 for aspirin and 822 for placebo, as 152 
(8.6%) patients withdrew consent and four patients (0.2%) were lost to follow-up. For 
the primary outcome (PE with delivery before 37 weeks of gestation), we reported 
adjusted odds ratio (OR) with 95% CI, and for secondary outcomes OR with 99% CI 
(PE with delivery before 34 weeks, term PE, stillbirth, neonatal death, poor fetal 
growth).  
All patients participating in the randomised trial received follow-up phone calls 
at 16 and 28 weeks of gestation in order to assess the occurrence of side-effects 
and compliance to treatment and were advised to attend follow-up visits including 
blood pressure measurement, fetal growth assessment by ultrasound, evaluation of 
side-effects (which were strictly reported to the CCTU-UCL), as well as assessment 
of compliance by counting the remaining tablets at 22 to 24+6, 32 to 34+6 and 36 to 
36+6 weeks of gestation. 
Baseline characteristics were similar between the groups. Adherence to 
treatment was good, with 80% of the patients taking 85% or more of the tablets. 
Aspirin reduced the incidence of preterm PE by 62% (OR 0.38, 95% CI 0.20-0.74, 
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p=0.004). This reduction was also significant in the survival analysis. There was also 
a non-significant reduction in early-onset PE (OR 0.18, 99% CI 0.03-1.03), early-
onset fetal growth restriction (OR 0.53, 99% CI 0.16-1.77), stillbirth before 37 weeks 
(OR 0.78, 99% CI 0.31-1.95) and preterm placental abruption (OR 0.52, 99% CI 
0.06-4.91). The study was not powered for such secondary outcomes.  
There was no increase in side effects, fetal abnormalities or other adverse 
events in the aspirin group when compared to the placebo group.    
The results of the ASPRE trial confirm that daily aspirin initiated before 16 
weeks of gestation, at a dose of 150 mg per day, to high-risk patients identified by 
first trimester combined screening, reduces the incidence of preterm PE. This study 
has been cited several times since publication, and its results were practice-
changing, with increasing implementation of first trimester screening for PE 
worldwide and prescription of a higher dose of aspirin (150 mg) to high-risk patients 
compared to the commonly prescribed doses before publication (100 mg or less).  
New meta-analyses performed after the publication of the ASPRE trial 
including its results also confirm the beneficial dose-dependent effect of aspirin in the 
prevention of preterm PE (Roberge et al., 2018a; Seidler et al., 2018).          
 
Strengths and limitations 
Unlike previous trials, this was the first large multicentre, double-blind, 
placebo-controlled trial to include high-risk women by means of first trimester 
combined screening. Aspirin was initiated before 16 weeks and with a dose higher 
than usual based on the apparent dose-dependent effect in the prevention of 
preterm PE. Measurements of biomarkers were obtained in a standardised manner 
by trained operators. Adherence to treatment was carefully assessed during follow-
up visits, and compliance with the study protocol was rigorously monitored by an 
independent entity, the Comprehensive Clinical Trials Unit, University College 
London. An independent statistician performed the statistical analysis. Funding 
organisations had no role in study design, collection, analysis or interpretation of the 
data, or writing of the manuscripts. 
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The main limitation of the study is the lack of long-term follow-up of the 
offspring, as the outcome collection was limited to the early neonatal period. The 
incidence of preterm PE was lower than what was anticipated, possibly a 
consequence of differences between the demographic characteristics of the trial 
population and those of the cohort used in the development of the algorithm.   
 
Publication 
1. https://www.ncbi.nlm.nih.gov/pubmed/28657417 
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana 
C, Akolekar R, Cicero S, Janga D, Singh M et al. Aspirin versus Placebo in 
Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017;377: 613-
622. 
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5. Secondary analyses of the ASPRE trial
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 This chapter is comprised by five sections, each containing one publication 
with a secondary analysis of the ASPRE trial.  
  
5.1. Performance of combined screening during the ASPRE trial 
 This section includes a publication describing the performance of screening in 
the actual randomised study (Rolnik et al., 2017c). Of 26,941 women screened, 
1,144 (4.2%) were excluded due to loss of follow-up or study withdrawal (n = 716), 
miscarriage (n = 243) or termination of the pregnancy (n = 185), leaving 25,797 
patients in the study. During the randomised trial, the performance of screening was 
very similar to that of published studies using similar first trimester algorithms for 
prediction of PE (Poon et al., 2009a; Akolekar et al., 2013; O'Gorman et al., 2016b). 
The analysis was adjusted for the beneficial effect of aspirin by estimating the 
number of events (preterm PE) in those receiving treatment if aspirin had no effect. 
No significant effect of aspirin was seen on PE at term in the trial.  
 Using a risk cut-off of 1 in 100 to define the high-risk population, screening for 
PE had a detection rate of 76.7% for preterm PE and 43.1% for term PE, at a 
screen-positive rate of 10.5% and false-positive rate of 9.2%.  
 
Strengths and limitations 
The randomised controlled trial showed a significant effect of aspirin in 
reducing the incidence of preterm PE. The analysis in the evaluation of the screening 
had to be adjusted for this effect and, therefore, this was not a non-intervention 
validation study.  
 
Publication 
1. https://www.ncbi.nlm.nih.gov/pubmed/28741785 
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Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana 
C, Akolekar R, Cicero S, Janga D, Singh M et al. ASPRE trial: performance of 
screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017;50: 492-495. 
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5.2. Incidence of preterm preeclampsia in patients fulfilling 
ACOG and NICE criteria according to risk by the FMF algorithm 
This section is based on a publication that reports the rate of preterm PE in 
women that fulfil the screening criteria of the NICE guidelines and ACOG risk factors 
and compares the incidence of preterm PE in those that are screen-positive (risk > 1 
in 100) and screen-negative (risk ≤ 1 in 100) by the FMF algorithm in the first 
trimester.  
In this publication (Poon et al., 2018), a secondary analysis of the ASPRE 
study was performed including all women screened during the validation phase 
(O'Gorman et al., 2017b) and the randomised trial period (Rolnik et al., 2017b). In 
total, 34,573 singleton pregnancies delivering at ≥ 24 weeks of gestation were 
included, and 239 (0.7%) were affected by preterm PE.  
At least one of the ACOG risk factors was fulfilled in 64.5% of the population, 
and the incidence of preterm PE in this group was 0.97% (95% CI 0.85-1.11%); in 
the subgroup that was screen-positive by FMF (risk > 1 in 100), the incidence of 
preterm PE was 4.8% (95% CI 4.14-5.55%), whereas in the subgroup that screened 
negative by the FMF algorithm, the incidence of preterm PE was 0.25% (95% CI 
0.18-0.33%). At least one of the NICE guidelines high-risk factors was present in 
4.0% of the screened population, and the incidence of preterm PE in this group was 
5.17% (95% CI 4.13-6.46%); in the subgroups of screen-positive and screen-
negative by the FMF algorithm the incidence was 8.71% (95% CI 6.93-10.89%) and 
0.65% (95% CI 0.25-1.67%), respectively. At least two of the NICE guidelines 
moderate-risk factors were present in 6.8% of the study population and the incidence 
of preterm PE in this group was 1.74% (95% CI 1.28-2.35%); in the subgroups of 
screen-positive and screen-negative by the FMF algorithm the incidence was 4.91% 
(95% CI 3.54-6.79%) and 0.42% (95% CI 0.20-0.86%), respectively. 
These findings are consistent with our previous studies (O'Gorman et al., 
2017a; Al-Amin et al., 2018) that show that risk-based methods of screening are 
superior to current guidelines based solely on maternal characteristics and medical 
history. Additionally, it is important to highlight that screening negative by the FMF 
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algorithm in the first trimester is reassuring even in the presence of risk factors, such 
as the history of a previous pregnancy affected by PE.  
 The results of this study provide further evidence to support combined 
screening for PE. In women fulfilling criteria by history-based screening methods and 
with a low risk according to first-trimester risk calculation by the FMF algorithm, the 
risk of preterm PE is reduced to within or below background levels.  
 
Strengths and limitations 
This study included a large population and collected data prospectively on 
maternal characteristics and history, biophysical and biochemical markers in women 
attending routine care between 11 and 13 weeks, a range widely used for screening 
of chromosomal abnormalities and other major fetal malformations. Consistency on 
biomarkers measurement was maintained throughout the study following training of 
all investigators according to standardised protocol and adherence to the study 
protocol was monitored by an independent entity (CCTU-UCL). 
The main limitation of the study relates to the low number of cases of women 
with certain risk factors, such as systemic lupus erythematosus or anti-phospholipid 
syndrome, leading to wide confidence intervals for relative incidences. Nonetheless, 
there was a consistent reduction in the incidence of preterm PE in the FMF screen-
negative group compared to that in the screen-positive group.   
 
Publication 
2. https://www.ncbi.nlm.nih.gov/pubmed/29380918 
Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, 
Andrade W, Efeturk T, Jani JC et al. ASPRE trial: incidence of preterm pre-eclampsia 
in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. 
Ultrasound Obstet Gynecol 2018;51: 738-742. 
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5.3. Influence of adherence to treatment on the effect of aspirin 
in the prevention of preterm preeclampsia 
 This section is based on a publication evaluating the impact of adherence to 
treatment on the beneficial effect of aspirin (Wright et al., 2017). Several studies 
have shown that patients who are adherent to drug therapies have better outcomes 
than those with poor compliance (Coronary Drug Project Research, 1980; Cramer, 
2002; Avorn, 2006; Simpson et al., 2006; Abbott-Mitchell, 2007; Cramer et al., 2008). 
Although randomised trials are often conducted on an intention-to-treat basis, their 
results could be influenced by the level of adherence to treatment of the participants.  
 In this secondary analysis of the ASPRE trial (Rolnik et al., 2017b), we 
examined the factors affecting compliance to treatment and its influence on the 
beneficial effect of aspirin in preventing preterm PE. Compliance was assessed by 
counting the tablets that were returned by the patients at each visit and by the 
participants’ reporting of tablet counts during each telephone interview. The total 
number of tablets taken was calculated by subtracting the number of tablets returned 
from the number of tablets prescribed. Compliance was calculated as a percentage 
of the reported intake to the total number of tablets that participants were expected 
to have taken between the date of randomisation and the date of the visit at 36 
weeks of gestation or the date of delivery if it occurred before 36 weeks. Compliance 
to the treatment of 90% or more was associated with a significantly greater reduction 
in the incidence of preterm PE (OR 0.24, 95% CI 0.09-0.65), when compared to 
compliance below 90% (OR 0.59, 95% CI 0.23-1.53). Adherence to treatment was 
positively associated with family history of PE and negatively associated with 
smoking, maternal age below 25 years, Afro-Caribbean and South Asian ethnic 
origins and history of PE in a previous pregnancy.  
 A possible explanation for the surprising finding of lower compliance among 
women with previous pregnancies affected by PE is that poor compliance may also 
be associated with an unknown attribute or with other maternal characteristics that 
are also associated with PE, such as ethnic origin. 
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Strengths and limitations 
The main limitation of this study is that it consists of a secondary analysis of 
the ASPRE trial, which was not adequately powered for such secondary analysis. 
Furthermore, it relied on the counting of tablets as a method of ascertaining 
compliance rather than a more objective measurement of a biomarker. There is a 
wide range of platelet activation and function assays that have been used to assess 
responsiveness to aspirin, but these assays suffer from limited reproducibility and 
poor agreement between them, and suboptimal suppression of platelet activation 
does not necessarily reflect poor compliance (Navaratnam et al., 2016). 
Nevertheless, the findings of this study support previous literature reports (Coronary 
Drug Project Research, 1980; Cramer, 2002; Avorn, 2006; Simpson et al., 2006; 
Abbott-Mitchell, 2007; Cramer et al., 2008) and are in agreement with the intuitive 
perception that good compliance results in a better effect of any given treatment. 
Future studies evaluating methods to ensure good compliance to treatment are 
necessary. 
 
Publication 
3. https://www.ncbi.nlm.nih.gov/pubmed/28888591  
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, de 
Alvarado M, Kapeti E, Rehal A, Pazos A et al. Aspirin for Evidence-Based 
Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin 
in prevention of preterm preeclampsia. Am J Obstet Gynecol 2017;217: 685 e681-
685 e685. 
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5.4. Subgroup analyses according to maternal characteristics 
and medical history 
 This section includes a publication in which we performed a secondary 
analysis of the ASPRE trial (Rolnik et al., 2017b) to examine whether there are 
differences in the effect of aspirin on the incidence of preterm PE according to 
maternal characteristics and medical history (Poon et al., 2017). Subgroup analyses 
were performed to assess evidence of differences in the effect of aspirin in 
subgroups of maternal age (< 30 and ≥ 30 years), BMI (< 25 and ≥ 25 kg/m2), ethnic 
background, method of conception, cigarette smoking, family history of PE, and 
history of chronic hypertension. 
 Interaction tests were performed on the full dataset of patients in the intention-
to-treat population, as well as on the subgroup of patients with good adherence to 
treatment (≥ 90% of the tablets consumed), with a Bonferroni correction for multiple 
comparisons. There was no evidence of heterogeneity in the aspirin effect in 
subgroups according to maternal characteristics and obstetric history. However, in 
patients with chronic hypertension, there was no evidence of reduction in the 
incidence of superimposed PE requiring delivery before 37 weeks of gestation, 
neither in the full dataset (10.2% in the aspirin group, 8.2% in the placebo group, 
adjusted OR 1.29, 95% CI 0.33-5.12), nor in the good adherence to treatment 
subgroup (adjusted OR 2.06, 95% CI 0.40-10.71). The test of interaction was highly 
significant in the subgroup with chronic hypertension and good compliance. Patients 
without chronic hypertension and with good adherence to treatment had a 95% 
reduction in the incidence of preterm PE (adjusted OR 0.05, 95% CI 0.01-0.41).  
 Regarding the biological plausibility, there is some evidence of differences 
between chronic hypertension and other factors in the pathogenesis of PE. Chronic 
hypertension, found in 1-2% of pregnancies, is the strongest risk factor for PE 
compared to other factors in maternal demographic characteristics and medical 
history (Wright et al., 2015b). The results of this study suggest that the beneficial 
effect of aspirin may not apply to women with chronic hypertension, favouring the 
hypothesis that in this group of patients an impaired cardiovascular system may be 
implicated in the origin of the disease (Kalafat and Thilaganathan, 2017). In chronic 
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hypertension, there is endothelial dysfunction and inflammation even before 
pregnancy and it is possible that in this condition PE can develop in the absence or 
less severe degree of impaired placentation because the pre-existing endothelial 
dysfunction is exacerbated by the physiological changes of pregnancy (Roberts and 
Hubel, 2009; Brandes, 2014; Panaitescu et al., 2017). 
   
Strengths and limitations 
The main limitation of this study is that it consists of a secondary analysis of 
the ASPRE trial, which was powered for a global test of the aspirin effect in a high-
risk population. Subgroup analyses will inherently have lower statistical power, and 
only more substantial interaction effects are likely to be identified. Furthermore, this 
problem is exacerbated by the need to account for multiple comparisons using a 
conservative technique such as Bonferroni correction. It is reassuring that the effect 
of aspirin was consistent across maternal characteristics and history factors other 
than chronic hypertension, but the broad confidence intervals do not allow the 
exclusion of other clinically important interaction effects.   
More studies are needed to investigate novel treatments in women with 
chronic hypertension and for the prevention of term PE, and to identify high-risk 
women who do not benefit from aspirin intake. Ongoing trials are now evaluating the 
possible beneficial effect of pravastatin, metformin and esomeprazole in the 
prevention of PE.  
 
Publication 
4. https://www.ncbi.nlm.nih.gov/pubmed/28784417  
Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, 
Akolekar R, Shearing S, De Stefani L et al. Aspirin for Evidence-Based Preeclampsia 
Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups 
of women according to their characteristics and medical and obstetrical history. Am J 
Obstet Gynecol 2017;217: 585 e581-585 e585. 
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5.5. Effect of aspirin on the length of stay in the neonatal 
intensive care unit 
 In the ASPRE trial, the use of aspirin significantly reduced the incidence of 
preterm PE by more than 60% when compared to placebo (Rolnik et al., 2017b). 
Surprisingly, however, despite the reduction in the incidence of PE, the rate of 
admission to the neonatal intensive care unit (NICU) was not significantly affected 
(OR 0.93, 95% CI 0.62-1.40).  
In the publication included in this section (Wright et al., 2018), we report a 
secondary analysis of the impact of treatment with aspirin on the length of stay in 
NICU. In the trial, there were 1,620 participants included in the final analysis, and 
these pregnancies resulted in 1,571 live births. The total length of stay in NICU was 
compared between the two intervention groups, as were the average lengths of stay 
in NICU among infants that were admitted and in the whole trial population (defining 
length of stay in NICU as zero days for infants who were not admitted to NICU). 
Bootstrapping was used for the comparison of the mean length of stay.  
 The total length of stay was substantially longer in the placebo group than in 
the aspirin group (1,696 and 531 days, respectively). The mean duration of stay 
among infants admitted to NICU was 31.4 days in the placebo group and 11.1 days 
in the aspirin group, a mean difference of 20.3 days (95% CI 7.0-38.6, p=0.008). 
This difference was mainly due to the reduction of PE requiring delivery before 32 
weeks of gestation, which contributed to 83.3% of the total length of stay in NICU. 
Overall, in the whole population, including zero lengths of stay for those that were 
not admitted to NICU, the mean length of stay was longer in the placebo than aspirin 
group (2.06 vs 0.66 days; reduction of 1.4 days [95% CI 0.45-2.81; p=0.014]). This 
corresponds to a reduction in length of stay of 68% (95% CI 20-86%). Since babies 
may be admitted to NICU for observation only and soon be discharged, length of 
stay is probably a better indicator of morbidity and, perhaps, predictor of long-term 
adverse outcomes. 
In a population of 10,000 pregnancies undergoing first-trimester screening for 
PE, 1,000 women would be classified as high risk with the expected screen-positive 
rate of 10%. Had these high-risk women not received aspirin, the expected total 
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length of stay in NICU would be 2,060 days, whereas if they had, the expected total 
length of stay in NICU would be 660 days. If the daily cost of the stay in NICU were 
£2,000, the cost saving from such care by a policy of screening 10,000 pregnancies 
and treating the high-risk group with aspirin would be £2,000 x (2,060 – 660) = 
£2,800,000. This is equivalent to £280 per patient screened, which is well in excess 
of the cost of screening and treating with aspirin. This calculation is based only on 
the reduction of length of admission in NICU, without considering a possible 
reduction in other prematurity-associated adverse neonatal outcomes that carry a 
significant burden, such as chronic lung disease and cerebral palsy.  
 Although it is difficult to estimate the cost-effectiveness of a policy of 
screening while the effect of such policy on neonatal outcomes is not well-
established in the literature, a cost-effectiveness study published in 2012 
demonstrated that screening would be cost-effective under various scenarios 
(Shmueli et al., 2012). Another recent study found screening and subsequent 
treatment of high-risk patients to be cost-saving when compared to absence of 
screening (Ortved et al., 2018).  
Effective first-trimester screening is provided by a combination of maternal 
demographic characteristics and medical history, and measurement of MAP, UtPI 
and PLGF. Recording of medical history and measurement of BP are an integral part 
of current prenatal care. The marginal cost of PLGF in a screening scenario, when 
the equipment is already in place, is estimated at £10 per patient. Measurement of 
UtPI can be carried out by the same sonographers and ultrasound machines used 
for the routine scan at 11 to 13 weeks of gestation; however, the sonographers will 
require training, and the measurement would add two to three minutes to the current 
20-30 minutes used for the scan. 
  
Strengths and limitations 
This was a secondary analysis of the ASPRE study. The trial was powered to 
detect differences between the treatment arms on the incidence of the primary 
outcome (preterm PE). Therefore, the statistical power for the detection of less 
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common outcomes, such as admission to NICU and length of stay in this unit is 
inevitably poor.  
The findings that infants born before 32 weeks of gestation contributed to 
more than 80% of the total length of stay in NICU, that the incidence of delivery 
before 32 weeks was lower in the aspirin group and that, as a consequence, the total 
length of stay in NICU was substantially reduced in the aspirin group are not 
surprising.  
Future trials, powered for specific neonatal outcomes, as well as long-term 
follow-up studies and meta-analyses, will be important to demonstrate the effect of 
aspirin in improving other neonatal outcomes due to the reduction of iatrogenic 
extreme prematurity.  
 
Publication 
5. https://www.ncbi.nlm.nih.gov/pubmed/29505771  
Wright D, Rolnik DL, Syngelaki A, de Paco Matallana C, Machuca M, de 
Alvarado M, Mastrodima S, Tan MY, Shearing S, Persico N et al. Aspirin for 
Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in 
the neonatal intensive care unit. Am J Obstet Gynecol 2018;218: 612 e611-612 
e616. 
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6. Arguments against universal prophylaxis with 
aspirin
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 With increasing evidence that aspirin reduces the incidence of preterm PE 
and the publication of the results of the ASPRE trial (Rolnik et al., 2017b), there is 
now little doubt as to its beneficial effect in pregnancies at high risk for PE. For this 
reason, some authors have been suggesting that, given the clear benefit, the low 
cost and the favourable safety profile of aspirin, this medication should be given to all 
pregnant women (Werner et al., 2015; Mone et al., 2017), arguing that the screening 
test is complex and expensive. 
 In a recent editorial (Rolnik et al., 2017a), we have summarised the main 
findings of the literature on this matter along with the results of the ASPRE study, 
highlighting some of the issues that would be faced in a policy of universal 
prophylaxis: 
 Efficacy: Aspirin is highly effective in reducing preterm PE when given to 
women at increased risk from before 16 weeks of gestation and at doses higher 
than 100 mg. Consistent evidence concerning its efficacy in the general 
obstetric population including low-risk women is currently lacking. In fact, the 
results of the ASPRE trial indicate that the number needed to treat (NNT) when 
aspirin is given to women identified as being at high risk is 38. If we gave 
aspirin to all pregnant women regardless of their risk and assumed that efficacy 
and compliance would be maintained within the general obstetric population, 
which is unlikely, the NNT would be 202. Preterm PE affects 0.7% to 0.8% of 
the pregnancies (O'Gorman et al., 2017a; Rolnik et al., 2017c), and more than 
99% of the women would not benefit from aspirin use.  
 Adherence to treatment: Very few studies evaluated adherence to treatment 
among women without a perceived high risk for developing PE. Nevertheless, 
pregnant women are naturally reluctant to take medication unnecessarily or in 
the absence of a significant risk factor for adverse pregnancy outcome, due to 
concerns regarding safety for the fetus (Nordeng et al., 2010; Lynch et al., 
2018). A randomised trial in which aspirin or placebo were given to nulliparous 
women with no other risk factors listed as inclusion criteria reported poorer 
compliance rates (Subtil et al., 2003). Another trial that recruited 3,647 of all 
women attending antenatal clinics between 12 and 32 weeks of gestation 
reported that only 55% of the participants had compliance above 80% (Rotchell 
et al., 1998). 
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 Long-term safety: The vast majority of the studies performed to date, including 
the ASPRE trial, have not shown an increase in serious side-effects or adverse 
events for both the mother and the child, and aspirin is considered a safe 
medication in pregnancy. However, information on long-term outcomes for 
women exposed to aspirin in pregnancy and their children is scarce. Although a 
previous study has shown no increase in mortality at two years of age  with the 
use of aspirin at a daily dose of 60 mg throughout pregnancy (CLASP 
Collaborative Group, 1995), other authors have raised concerns regarding 
long-term outcomes for the infant in observational studies, but these findings 
may have been subjected to biases due to the influence of confounders 
(Petersen et al., 2018). In non-pregnant adults, long-term use of aspirin has 
been shown to increase the incidence of haemorrhagic events (De Berardis et 
al., 2012), and a recent meta-analysis has shown a possible hazardous effect 
of aspirin in increasing the risk of placental abruption when the medication is 
initiated after 16 weeks of gestation (Roberge et al., 2018b).  
 
For the reasons mentioned above, caution is recommended, and the 
widespread prescription of aspirin to millions of pregnant women without targeting 
a specific high-risk population should be avoided. 
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7. Cell-free DNA in screening for preeclampsia
 
62 
This chapter is based on two publications. Numerous studies have been 
investigating new markers that may enhance predictive algorithms in the near future. 
Given that predictive algorithms detect about 75% of the cases of preterm PE, there 
is room for improvement. Although new markers might be different in patients with 
PE compared to normotensive controls, their effects on predictive models need to be 
tested in combination with established markers with which they may interact and 
overlap.  
Several studies have reported that in patients with established PE both total 
and fetal cell-free DNA are higher than in normotensive controls (Lo et al., 1999; 
Zhong et al., 2001; Alberry et al., 2009; Miranda et al., 2013; Zeybek et al., 2013), 
possibly due to accelerated apoptosis of placental cells in cases of PE. Following the 
discovery of fetal DNA on maternal blood (Lo et al., 1997), cell-free fetal DNA testing 
has been rapidly incorporated into clinical practice due to its high accuracy in 
detecting fetal chromosomal abnormalities. Higher incidence of PE was also found 
among patients with failed cell-free DNA test due to a low fetal fraction (Chan et al., 
2017). There is conflicting data as to whether these altered levels precede the onset 
of the disease (Martin et al., 2014).  
In the first study, published in 2015, we performed a case-control study of 20 
cases of early PE, 20 cases of late PE and 200 normotensive controls, in which 
neither the quantities of cell-free DNA nor the fetal fraction were different in patients 
who developed PE compared to normotensive controls after adjustment for 
confounders (Rolnik et al., 2015).  
In a larger cohort study, however, our group demonstrated a clear association 
of fetal fraction with first trimester markers for PE and predicted risks (Rolnik et al., 
2018), even after adjustment for maternal characteristics and gestational age. This 
suggests that fetal fraction on cell-free DNA testing also reflects placentation. 
However, the degree of overlap with other markers and a possible role of 
incorporating cell-free DNA or fetal fraction into predictive models are yet to be 
determined. The possibility of using this test in patients undergoing cell-free DNA 
testing for aneuploidies screening instead of first trimester combined screening 
should be addressed in future research. 
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Strengths and limitations 
In the case-control study, the number of pregnancies affected by PE may be 
inadequate for concluding that cell-free DNA levels are not altered in all types of PE. 
The second study, despite the large number and the associations found, is 
retrospective in nature and did not include pregnancy outcomes. Therefore, no 
conclusions regarding differences in cell-free DNA between patients who developed 
PE and normotensive controls can be drawn. 
The search for new markers remains the focus of several studies, and with 
the increasing use of cell-free DNA testing for aneuploidy screening, the potential 
role of this test in improving current predictive algorithms should be explored further. 
  
Publications 
1.  https://www.ncbi.nlm.nih.gov/pubmed/25252010 
Rolnik DL, O'Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC. 
Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obstet 
Gynecol 2015;45: 106-111. 
 
2. https://www.ncbi.nlm.nih.gov/pubmed/29318732 
Rolnik DL, da Silva Costa F, Lee TJ, Schmid M, McLennan AC. Association 
between fetal fraction on cell-free DNA testing and first trimester markers for pre-
eclampsia. Ultrasound Obstet Gynecol 2018, DOI 10.1002/uog.18993. 
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8. Conclusions and future perspectives
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8.1. Clinical implementation of screening and recommendations 
for clinical practice 
The clinical implementation of first-trimester combined screening for PE 
requires specific training for MAP and UtPI measurements and testing PLGF on 
maternal blood, but the addition of these biomarkers would lead to a minimal 
increase in costs in settings where first-trimester combined screening for 
chromosomal abnormalities is routinely performed.  
Different combinations of markers with partial models of screening can be 
used with reasonable detection rates in low-resource settings where applying the full 
algorithm may be challenging. In settings where analysing maternal serum 
biochemistry is challenging, for instance, a combination of maternal history with 
biophysical markers such as MAP can lead to reasonable detection rates. Similar to 
screening for chromosomal abnormalities, a quality assurance process for 
biomarkers measurement should be in place, and the cut-off selected by different 
health systems may vary depending on the resources and the baseline risk of PE in 
a given population.  
Aspirin at doses of less than 100 mg does not seem to be effective in the 
prevention of preterm PE and therefore the daily dose used should be higher than 
100 mg (ideally 150 mg daily). Because the standard dose varies from country to 
country, adjustments may be necessary. For example, in the UK, where the standard 
dose is 75 mg, and in the USA, where the standard dose is 81 mg, two tablets can 
be taken daily. In countries where the standard dose is 100 mg, the daily 
recommended intake should be one tablet or one tablet and a half.  
For successful clinical implementation, it is crucial to achieve a global 
consensus regarding screening, dose and timing of aspirin prescription in light of the 
emerging body of evidence. 
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8.2. Future studies 
Identifying which maternal characteristics predict poor response to aspirin and 
research on new preventive measures will be essential to find alternative treatments 
for this specific group and for women with chronic hypertension. Additionally, term 
PE is responsible for the majority of the burden of the disease, as this form of PE is 
more common than preterm PE (Duley, 2009; Bahado-Singh et al., 2017). Its 
prediction is poor (Akolekar et al., 2013; O'Gorman et al., 2016b) and its incidence is 
not reduced by aspirin intake (Roberge et al., 2012b; Rolnik et al., 2017b). 
Therefore, new predictive markers for term PE and novel preventive strategies, 
including the use of pravastatin, metformin and proton-pump inhibitors such as 
esomeprazole are subject of ongoing research (Cluver et al., 2015; Brownfoot et al., 
2016a; Brownfoot et al., 2016b; Syngelaki et al., 2016; Girardi, 2017; Kaitu'u-Lino et 
al., 2018). 
In summary, further research needs to be undertaken to identify women with 
poor response to aspirin, to improve the prediction of term PE and to investigate new 
preventive strategies for term PE and for PE in women with chronic hypertension.  
 
8.3. Final considerations 
Preeclampsia is a serious complication of pregnancy, and a significant 
proportion of the cases that will require premature delivery can be identified in the 
first trimester through a screening test that combines maternal characteristics, 
medical history and biophysical and biochemical markers. This approach is superior 
to current guidelines based on maternal characteristics and history alone.  
The ASPRE trial is a landmark study in the investigation of screening and 
prevention of preeclampsia. It was well designed and the first multicentre trial to 
apply combined screening in a large population. The intervention was carefully 
chosen considering the latest evidence. Its impact is reflected in the publication of 
the results in a high impact medical journal, the large number of citations in a short 
period time and, above all, in the changes in clinical practice worldwide.  
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Aspirin, at a daily dose of 150 mg and given to high-risk patients from 11 to 14 
weeks until 36 weeks of gestation, reduces the incidence of the severe forms of PE 
that require premature delivery and, as a consequence, the length of stay in NICU, 
saving costs that clearly exceed the cost of screening. The effect of the medication, 
unsurprisingly, depends on the adherence to treatment and is questionable in 
patients with chronic hypertension.  
Universal prophylaxis with aspirin that has been suggested in the literature is 
problematic, as it would probably result in low compliance and long-term safety data 
is currently lacking.  
Further research is warranted to improve current predictive algorithms and to 
investigate new preventive measures for term PE, and for preterm PE in specific 
groups of women. 
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